Usefulness of liquid biopsy biomarkers from aqueous humor in predicting anti-VEGF response in diabetic macular edema : results of a pilot study
Udaondo, Patricia (Hospital Universitari i Politècnic La Fe (València))
Hernández, Cristina (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Brianso-Llort, Laura (Universitat Autònoma de Barcelona)
García-Delpech, Salvador (Hospital Universitari i Politècnic La Fe (València))
Simó-Servat, Olga (Universitat Autònoma de Barcelona. Departament de Medicina)
Simó Canonge, Rafael (Universitat Autònoma de Barcelona. Departament de Medicina)

Data:	2019
Resum:	The objective was to investigate the usefulness of the "liquid biopsy" of aqueous humor (AH) to predict the clinical response after intravitreal injections (IVT) of anti-VEGF agents for treating diabetic macular edema (DME). For this purpose, AH samples obtained during the first anti-VEGF IVT from 31 type two diabetic patients were analyzed. Patients were classified into three groups according to their anti-VEGF response: rapid responders (n = 11), slow responders (n = 11), and non-responders (n = 9). In addition, patients (n = 7) who showed good response to corticosteroids but a delayed or no response to anti-VEGF therapy were analyzed. Levels of 17 different cytokines, chemokines, and growth factors in AH were measured using a multiplex immunoassay. We found higher concentrations of VEGF in rapid responders to anti-VEGF therapy compared to non-responders. In addition, slow responders to anti-VEGF treatment showed higher levels of inflammatory markers than rapid responders, but did not reach statistical significance. Finally, those patients who responded to corticosteroids but not to anti-VEGF therapy showed significantly lower levels of VEGF than patients with rapid response (p = 0. 01). In conclusion, "liquid biopsy" of AH could be useful to determine whether the predominant pathogenic event is primarily angiogenic or inflammatory in nature. This approach would allow physicians to select a more rational and cost-effective treatment. Further studies to validate these preliminary results are warranted.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Diabetic macular edema ; Anti-VEGF agents ; Aqueous humor ; Biomarkers ; VEGF ; Inflammation ; Personalized medicine
Publicat a:	Journal of clinical medicine, Vol. 8 (2019) , p. 1-9, ISSN 2077-0383

DOI: 10.3390/jcm8111841
PMID: 31684007

9 p, 621.4 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats